Nuvelo Reports Results From Phase 3 NAPA Program In Acute Peripheral Arterial Occlusion

(RTTNews) - Nuvelo Inc. announced results from the Phase 3 NAPA or Novel Arterial Perfusion with Alfimeprase program evaluating alfimeprase in acute peripheral arterial occlusion or PAO.
According to the company, 34.9% of patients receiving alfimeprase achieved primary endpoint of 30-day open vascular surgery avoidance in the NAPA-2 clinical trial, whereas 37.2% of patients receiving intra-thrombus placebo and 18.4% of patients receiving peri-thrombus placebo achieved primary endpoint.